Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xeris Biopharma reports record revenue growth and outlines future plans

Xeris Biopharma's Q4 2022 performance reflects strong revenue growth and pipeline advancements, supported by a positive 2023 revenue guidance.
While facing challenges such as competitive pressures and market dynamics, the company's focus on innovation and patient-centric strategies positions them for future success.
Opportunities lie in addressing concerns around product growth, enhancing physician engagement, and pursuing new drug development for long-term growth.

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.

Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2024 and recent events. “We grew total product revenue 25% in the first quarter compared to last year, despite an estimated $3 million negative impact to Gvoke revenue from the Change Health.

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to leverage Xeris' novel XeriSol technology for the development and commercialization of a glucagon product to be integrated into Beta Bionics' proprietary bi-hormonal pump and pump systems.

Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol™ technology for use in Beta Bionics' proprietary.

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the.

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equi.

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit “Events”.

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growth. Risks include competition from larger healthcare companies and the FDA approval of a generic version of one of Xeris' products, Keveyis.

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Xeris Biopharma Holdings Inc. (NASDAQ:XERS ) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Paul Edick - Chairman, Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President, Investor Relations Conference Call Participants Oren Livnat - HC Wainwright Glen Santangelo - Jefferies Chase Knickerbocker - Craig Hallum Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Operator Hello everyone and welcome to the Xeris fourth quarter and full year 2023 financial results conference call and webcast. My name is Emily and I'll be coordinating your call today.

Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing borrowing interest rates. Under this agreement, Xeris secured $200 million in capital upfront, with the option to access an additional $15.2 million to redeem its outstanding convertible senior notes due in 2025.

Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump

Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2023 and recent events. “2023 was another year of exceptional performance and growth for Xeris. We executed on all fronts: our commercial products grew over 40%; our intern.

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris $200.0 million of capital at close and the ability to draw down ano.

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Xeris (XERS) Might Surprise This Earnings Season

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that d.

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please v.

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.

Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

Amgen

Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of teprotumumab using Xeris' XeriJect technology.   The collaboration aims to address Thyroid Eye Disease (TED), a severe, progressive, and potentially vision-threatening rare autoimmune disorder.

Xeris Biopharma inks exclusive worldwide license agreement with Amgen for XeriJect in thyroid eye disease

Xeris Biopharma (NASDAQ: XERS ) stock is heading higher on Wednesday after the company announced an exclusive worldwide license agreement with Amgen (NASDAQ: AMGN ). That agreement allows Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab, known as TEPEZZA in the U.S. This will be done with Xeris Biopharma's XeriJect technology for Thyroid Eye Disease.

Why Is Xeris Biopharma (XERS) Stock Up 12% Today?

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris' XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progress.

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aqueous formulations for certain drugs, improving stability and solubility. The company has seen significant revenue growth, with three commercially approved drugs generating $42 million in revenues in Q3 2023.

Xeris Biopharma: Speculative Buy, Size Your Position Accordingly

AECOM

Academy Sports and Outdoors

Flywire Corp

Guardant Health Inc

MicroStrategy Incorporated

Nano Dimension

2023 was dominated by the Magnificent Seven stocks, which has left investors wondering how much higher mega-cap stocks can go. Investors worry that growth is nearing a peak or perhaps reversing.

7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it remains on track to be cashflow positive in the fourth quarter of 2024 as it updated its revenue and cash position guidance for its 2023 financial year. Ahead of investor meetings in San Francisco next week, the growth-oriented biopharmaceutical company said it expects to report total revenue at the top of its previous guidance range of $160 million to $165 million.

Xeris Biopharma updates FY23 outlook; remains on track for 4Q positive cash flow

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2023. The Company expects to be cashflow positive in the fourth quarter, report total revenue at.

Xeris Biopharma Updates Its Outlook for 2023

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris' Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit “Events”.

News for Xeris Biopharma Holdings Stock (XERS)